First Trust Advisors LP Boosts Holdings in Perrigo Company plc $PRGO

First Trust Advisors LP grew its stake in Perrigo Company plc (NYSE:PRGO) by 125.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,496,244 shares of the company’s stock after purchasing an additional 832,686 shares during the quarter. First Trust Advisors LP’s holdings in Perrigo were worth $16,070,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of PRGO. Amundi lifted its stake in Perrigo by 11.7% in the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after buying an additional 556 shares in the last quarter. Kestra Investment Management LLC increased its stake in Perrigo by 57.1% during the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after buying an additional 642 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in shares of Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after acquiring an additional 786 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after acquiring an additional 1,014 shares during the last quarter. Finally, Covestor Ltd lifted its position in shares of Perrigo by 14.4% in the fourth quarter. Covestor Ltd now owns 8,991 shares of the company’s stock valued at $125,000 after acquiring an additional 1,129 shares in the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PRGO. Weiss Ratings raised Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $19.33.

Perrigo Trading Up 1.4%

PRGO opened at $10.45 on Thursday. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. The company’s 50 day simple moving average is $10.57 and its two-hundred day simple moving average is $11.68. Perrigo Company plc has a 1-year low of $9.23 and a 1-year high of $28.22. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -0.80, a price-to-earnings-growth ratio of 1.22 and a beta of 0.51.

Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The business had revenue of $841.80 million during the quarter, compared to analyst estimates of $1.04 billion. During the same period in the prior year, the business earned $0.60 earnings per share. The business’s revenue was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Analysts expect that Perrigo Company plc will post 2.11 EPS for the current fiscal year.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.